Quality-of-Life Outcomes After Primary Androgen Deprivation Therapy: Results From the Prostate Cancer Outcomes Study

Potosky, Arnold L.; Knopf, Kevin; Clegg, Limin X.; Albertsen, Peter C.; Stanford, Janet L.; Hamilton, Ann S.; Gilliland, Frank D.; Eley, J. William; Stephenson, Robert A.; Hoffman, Richard M.

doi:10.1200/jco.2001.19.17.3750

Cited by 235 publications

(138 citation statements)

References 20 publications

Supporting

Mentioning

128

Contrasting

Unclassified

Order By: Relevance

“…A common practice outside clinical trials is to apply AD for 3 -6 months, but treatments as long as several years are also practised. The use of AD appears to be most common in early-stage disease (T1 -T2), as reported by Potosky et al (2001), these being patients who are usually long-term survivors in PC. At least 22 000 PC men each year in the US have been estimated to receive hormonal therapy (Potosky et al 2001).…”

mentioning

confidence: 92%

Androgen deprivation and cognition in prostate cancer

et al. 2003

View full text Add to dashboard Cite

Androgen deprivation (AD) is commonly used in neoadjuvant and adjuvant setting with prostate cancer (PC) radiotherapy. This prospective study assessed whether cognitive functioning is impaired during 12 months of AD therapy. Longitudinal testing of 25 patients treated with AD and curative radiotherapy was undertaken at baseline, and at 6 and 12 months. CogniSpeed r software was used for measuring attentional performances. Other cognitive performances were evaluated using verbal, visuomotor and memory tests. The Beck depression inventory was employed to evaluate depressive mood and EORTC QLQ-C30 for quality of life (QoL). During longitudinal testing of the AD group, no impairment in cognitive performances was found. Instead, improvement was observed in object recall (immediate, P ¼ 0.035; delayed, Po0.001), and in semantic memory (P ¼ 0.037). In QoL, impairment in physical function was observed. Androgen deprivation of 12 months appears to be associated with preserved cognitive functioning, although physical impairment occurs. These results have implications for counseling and psychosocial support of patients in the context of treatment options in PC.

show abstract

mentioning

confidence: 92%

Androgen deprivation and cognition in prostate cancer

et al. 2003

View full text Add to dashboard Cite

show abstract

“…Potosky et al 49 in a prospective cohort of 431 men, showed that the percentage of men who were sexually inactive increased from 48% to 83% after orchiectomy and from 45% to 80% after gonadotropinreleasing hormone agonist administration. Marumo et al 50 observed in nine sexually active prostate cancer patients who underwent ADT with 3.75 mg of leuprorelin acetate every 4 weeks as monotherapy, that a reduction in serum testosterone concentrations to levels inferior to 10 ng dl 21 at 12 weeks, preceded total suppression of sexual activity (no intercourse for 12 weeks during treatment) in all patients.…”

Section: Sexual Activitymentioning

confidence: 99%

Impact of androgen deprivation therapy on sexual function

Mazzola

Mulhall²

2012

Asian J Androl

View full text Add to dashboard Cite

Many patients with prostate cancer for whom androgen deprivation therapy (ADT) is indicated are young and desire to remain sexually active. In such patients, the side effects of androgen therapy on sexual function can be a source of serious reduction in overall quality of life. Providing the appropriate treatment options in this patient population is therefore essential. Nevertheless, treating such patients is challenging and an understanding of the underlying mechanisms of sexual physiology and pathophysiology is crucial to optimal patient care. In this paper, we reviewed what was known regarding the effects of ADT on sexual function in animal models and we also provided a detailed review on the effects of ADT on sexual health in humans and its treatment.

show abstract

“…Besides hot flushes and sexual dysfunction, a higher incidence of breast swelling with LHRH analogues compared to orchiectomy has also been reported (24.9 % vs. 9.7 %) [7]. In addition, contrary to popular belief, LHRH agonist therapy significantly decreases the testicular weight.…”

Section: Discussionmentioning

confidence: 99%

Can Subepididymal Orchiectomy Re-emerge as the Treatment of Choice in Patients with Advanced Prostatic Carcinoma?

Agarwal

Agrawal

2012

Indian J Surg

View full text Add to dashboard Cite

To study the effectiveness of bilateral subepididymal orchiectomy compared to bilateral simple and subcapsular orchiectomy in terms of androgen ablation, control of disease progression and esthetic superiority. 114 patients of advanced prostatic carcinoma (T3, T4, M1) were randomized to 3 groups-Group A: bilateral simple orchiectomy (38 patients), Group B: bilateral subcapsular orchiectomy (38 patients), & Group C: bilateral subepididymal orchiectomy (38 patients). Serum PSA and serum testosterone values were checked pre-operatively and at 3 months follow-up. Patients' esthetic satisfaction was scored on a quality of life scale of 1-5. In Groups A, B and C, at 3 months the post-operative mean serum testosterone values were 34.7, 38.1 and 36.7 ng/ dl (p00.0524); and mean serum PSA values were 4.2, 3.9 and 3.4 ng/ml (p00.09) respectively, the differences not being statistically significant. On esthetic satisfaction scale the average scores were 1.8, 2.7 and 4.0 respectively, the difference being highly significant (p<0.0001). Subepididymal orchiectomy maintains esthetic appearance of scrotum and provides superior patient satisfaction as compared to standard total and subcapsular orchiectomy, while achieving equal efficacy. Bilateral sub-epididymal orchiectomy may thus be considered procedure of choice to achieve androgen ablation in advanced prostatic carcinoma.

show abstract

Quality-of-Life Outcomes After Primary Androgen Deprivation Therapy: Results From the Prostate Cancer Outcomes Study

Cited by 235 publications

References 20 publications

Androgen deprivation and cognition in prostate cancer

Androgen deprivation and cognition in prostate cancer

Impact of androgen deprivation therapy on sexual function

Can Subepididymal Orchiectomy Re-emerge as the Treatment of Choice in Patients with Advanced Prostatic Carcinoma?

Contact Info

Product

Resources

About